Agoracom Blog

MedX $MDX.ca Announces Final Closing of $4 Million Convertible Debenture Loan Notes Non-brokered Private Placement $DMTK $LMD.ca $DOC.ca $DOCRF $WELL.ca $PRN.ca

Posted by AGORACOM-JC at 9:11 AM on Thursday, February 25th, 2021
Home - MedX Health
  • Closed on the final $1.4 million of the $4 million Non-brokered Private Placement of 80 Convertible Debenture Loan Notes
  • Each with a face value of $50,000, as originally announced in its Press Release dated January 25, 2021. Previous Closings were announced earlier in February 2021

MedX Health Corp. (“ MedX ” or the “ Company ”) (TSX-V: MDX) is pleased to announce that it has closed on the final $1.4 million of the $4 million Non-brokered Private Placement of 80 Convertible Debenture Loan Notes, each with a face value of $50,000 (“Convertible Notes”), as originally announced in its Press Release dated January 25, 2021. Previous Closings were announced earlier in February 2021.

Full Details of each of the Closings are as follows:

  • First Closing on January 27, 2021: $2 million, with cash commissions of $114,000 and issuance of 300,000 Broker Warrants;
  • Second Closing on January 28, 2021: $500,000, with cash commissions of $15,000 and issuance of 107,143 Brokers Warrants;
  • Third Closing on February 3, 2021: $100,000, with no cash commissions and no Brokers Warrants;
  • Fourth, and final Closing, on February 23, 2021: $1.4 million, with cash commissions of $81,000 and issuance of 578,576 Brokers Warrants.

The Convertible Notes will bear interest at 6% per year, payable Quarterly, and will mature on December 31, 2023 (the “Maturity Date”). The Convertible Notes may be converted, at the option of the Holder, into units at $0.14 per unit (“Unit”) at any time until the Maturity Date. Each Unit will be comprised of One (1) fully paid Common Share and One-half (1/2) of a Share Purchase Warrant. Each whole Share Purchase Warrant will be exercisable to purchase One (1) further Common Share at the price of $0.20, exercisable for a period expiring on the Maturity Date. The Convertible Notes, and any underlying securities, are subject to restriction from trading for a period of 4 months and one day from the respective dates of issuance. Qualified Agents received commissions in respect of subscriptions introduced by them by way of cash equal to 6% of funds so introduced, and issuance of agent’s warrants (“Agent’s Warrant(s)”) calculated by reference to 6% of the funds from subscribers introduced by such Agent. Each Agent’s Warrant, which is non-transferable, will be exercisable to acquire one Unit at $0.14 per Unit, at any time during the period up to the Maturity Date. A total of $210,000 of cash commissions were paid, and 985,719 Agent’s Warrants have been issued. The Agent’s Warrants, and any underlying securities, are restricted from trading for a period of four months and one day from their respective dates of issuance.

MedX’s CEO, Rob von der Porten stated, “We believe this financing clearly demonstrates a vote of confidence in our strategic direction and ability to be a leader in the teledermatology space. This funding is significant to furthering the development of our sales initiatives and advancing MedX’s Dermsecure TM platform to a wider global network.”

About MedX

MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin health with its SIAscopy on DermSecure™ telemedicine platform, utilizing its SIAscopy™ technology. SIAscopy is also imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada, FDA, TGA and CE cleared for use in Canada, the US, Australia, New Zealand, the European Union, Turkey and Brazil. MedX also designs, manufactures and distributes quality photobiomodulation therapeutic and dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain. www.medxhealth.com.

Read More: https://agoracom.com/ir/MDX/forums/discussion/topics/756059-medx-announces-final-closing-of-4-million-convertible-debenture-loan-notes-non-brokered-private-placement/messages/2305336#message

Red Light Holland $TRIP.ca $TRUFF iMicrodose Pack Receives Authorization for the First Legal Import and Sale of Psilocybin Truffles to Brazil $RVV.ca $PSYC $FTRP $BUZZ

Posted by AGORACOM at 8:53 AM on Thursday, February 25th, 2021
https://i.ibb.co/ZdKv64V/Red-Light-Holland-Square.jpg
  • iMicrodose packs, which contain 15g of Psilocybin Truffles, to be legally imported to Brazil
  • To be imported and sold in Brazil for Medical use
  • Approval and shipment represent a significant advancement in opening the legal and medically approved market for psilocybin in Brazil

Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTC: TRUFF) (“Red Light Holland” or the “Company“), an Ontario-based corporation engaged in the production, growth and sale of a premium brand of magic truffles to the legal, recreational market within the Netherlands, is extremely pleased to announce that Anvisa, Brazil’s National Health Regulatory Agency, has granted authorization for the Company’s iMicrodose packs, which contain 15g of Psilocybin Truffles, to be legally imported to Brazil via the ‘named patient import process’ for prescribed medical patient use.

“We are grateful for our collaborative relationship with Disruptive Pharma who worked closely with the Brazilian Health Regulatory Agency to secure authorization to import Red Light Holland’s iMicrodose packs, with our natural-occurring branded Psilocybin Truffles, to be imported and sold in Brazil for Medical use, as our branded iMicrodose packs have officially been prescribed by a doctor to a patient in Brazil,” said Todd Shapiro, CEO and Director of Red Light Holland. “This is a monumental day for the Company, and we are so proud to be a part of providing legal access of psilocybin to Brazil and for the first time having our product prescribed by a physician for medical use.”

Red Light Holland’s iMicrodose packs have been shipped to Disruptive Pharma’s MyPharma2Go logistics hub in the Netherlands to start their journey to Brazil. Once landed in Brazil, MyPharma2Go is expected to deliver the iMicrodose packs to a Brazilian patient as they have been pre-prescribed by a physician, before the end of March 2021.

This approval and shipment represent a significant advancement in opening the legal and medically approved market for psilocybin in Brazil, a country with a population of over 200 million people. Shapiro added: “This early process working alongside Disruptive Pharma’s MyPharma2Go.com, a large Brazilian online pharmaceutical and supplement distributor, has been an absolute pleasure and one we are thankful for. We are pleased to do our part to potentially be a part of positive change in Brazil, and to steal a line from Neil Armstrong: This is one micro step for man, one macro leap for mankind.”

Red Light Holland and Disruptive Pharma continue to work towards finalizing their proposed joint venture structure and agreement, as previously disclosed in the Company’s news release dated December 14, 2020. In consideration for Disruptive Pharma having met these initial milestones, the Company has agreed to issue to Disruptive Pharma, 3,000,000 common share purchase warrants, each warrant is exercisable into one common share of the Company at a price of $0.50 per share for a period of 2 years. 750,000 of these warrants have vested immediately based on Disruptive Pharma having fulfilled these milestones, the balance vest upon future milestones being met. These warrants and any underlying shares issued upon exercise, are subject to a statutory hold period of 4 months and 1 day.

Read More: https://agoracom.com/ir/RedLightHolland/forums/discussion/topics/756065-red-light-holland-imicrodose-pack-receives-authorization-for-the-first-legal-import-and-sale-of-psilocybin-truffles-to-brazil/messages/2305343#message

Xali Gold $XGC.ca Delineates Drilling Targets at El Dorado $FMG.ca $MEX.ca $AGI.ca $DSV.ca

Posted by AGORACOM at 8:35 AM on Thursday, February 25th, 2021

Xali Gold Corp. (TSXV:XGC) (“Xali Gold” and/or the “Company”) is pleased to advise that new drill targets have been delineated on the El Dorado Gold-Silver Project, located in Nayarit State, Mexico through the development of a new 3D geological model. The new model indicates high grade mineralization occurring in multiple parallel veins such that future mining could focus on several veins at once to potentially allow reduced mining costs. Drilling is planned to test potential lateral extensions to the high grade zone.

Permitting applications are in progress for the drilling which are expected to take 3 to 4 months to receive. Permit applications are also being prepared for the reopening of the historical Hundida Mine and should take 6 to 10 months to receive. Mineralization is planned to be shipped from this area to the nearby SDA plant under acquisition from Magellan Acquisitions.

The El Dorado vein system has a history of small-scale mining from two veins in the Hundido and El Dorado mines (see News Release April 28, 2020) but four veins with parallel high-grade zones have been delineated in the new model. Additionally, several vein targets have been identified along trend for follow-up exploration.

Prospero Silver Corp. (“Prospero”) explored the El Dorado property between 2010 and 2011. Their drilling intersected multiple steeply-dipping silicified mineralized zones extending from near-surface to the 180 metre (“m”) drilled depth and over a strike length of 440m.   Prospero intersected grades ranging from 3 to 40 grams per tonne (“gpt”) gold and 57 to 500 gpt silver over true widths ranging from 0.52 to 11.2 m. (http://www.candentegold.com/i/maps/sedardoc4391012.pdf)

Significant results reported by Prospero on Dec 10, 2010 included:

  • 16.17m grading 4.03 g/t gold, 204 g/t silver, 4.0% lead, and 1.75% zinc; and 2.32m grading 6.04 g/t gold and 140 g/t silver in hole DOR-10-11. (http://www.candentegold.com/i/maps/Prospero-NR–December-10,-2010.pdf)

Read More: https://agoracom.com/ir/XaliGold/forums/discussion/topics/756062-xali-gold-delineates-drilling-targets-at-el-dorado/messages/2305340#message

Candente Copper $DNT.ca Engages Ausenco for Desk Top Studies on Cañariaco Norte Higher Grade Copper Project $CDG.ca $FCX.ca $TECK.ca $FSUGY $PER.ca

Posted by AGORACOM at 8:30 AM on Thursday, February 25th, 2021
http://blog.agoracom.com/wp-content/uploads/2020/08/candente-copper-for-blog1.jpg

Candente Copper Corp. (TSX:DNT, BVL:DNT) (“Candente Copper”, “Company”) is pleased to announce that it has engaged Ausenco Engineering Canada Inc. (“Ausenco”) to conduct Desk Top Studies to identify and define a smaller, higher grade, start up option for Cañariaco with a smaller initial capital expenditure (“CapEx”) and accelerated payback period. This study is expected to take 4 to 6 weeks to complete.

Assuming favourable results from the Desk Top Studies the Company would look to move into a Preliminary Economic Assessment (“PEA”) on the Revised Project Concept which would be expected to take approximately 4 months to complete. The Company is fully funded for both levels of studies. (for more details please see News Release No. 126 dated February 22nd, 2021).

Ausenco is globally recognised for providing consulting, project delivery, and asset operations services to the international mining sector including high performance copper processing and infrastructure projects. Ausenco has a 30-year track record in delivering specialized end-to-end solutions which are proven to lower capital and operating costs, reduce construction time and improve plant efficiencies.

Ausenco’s project experience ranges from small conceptual studies for new developments through to the construction of large scale minerals processing facilities. In Peru, Ausenco’s experience includes providing Engineering, Procurement and Construction Management services to design, construct, and commission the 25 million tonnes per year concentrator and associated infrastructure for the Constancia Copper Molybdenum Project owned by Hudbay.

Furthermore, Ausenco is currently in the final stages of providing Engineering, Procurement and Construction Management services to design, construct, and commission two processing facilities that will process 6 million tonnes per year of copper sulfide ore and 12 million tonnes per year of oxide ore via solvent extraction and oxide leaching facility (along with associated infrastructure) for the Mina Justa project owned by Marcobre S.A.C. (controlled by Minsur S.A.).

Recently, Mantos Copper Holding has engaged Ausenco for the engineering, procurement and construction (EPC) the 30,000 tonne per day copper concentrator plant and related infrastructure at the Mantoverde Development Project in Chile.

Read More: https://agoracom.com/ir/CandenteCopper/forums/discussion/topics/756063-ausenco-engaged-for-desk-top-studies-on-ca-ariaco-norte-higher-grade-project/messages/2305341#message

$HPQ.ca Receives its First Mini-Generator Set Based on Clean Hydrogen Produced by Simply Combining Water and a Powder Bag $ENPH $BE $NNO $PYR

Posted by AGORACOM-JC at 8:20 AM on Thursday, February 25th, 2021
  • While continuing to work with Apollon on the development of new generations of more efficient silicon powders for hydrogen production, HPQ signed a Memorandum of Understanding with Apollon and Pragma to study the commercial potential of the TREKHY® autonomous power generator in Canada.
  • The TREKHY® provides energy on demand.
  • The system uses a compact fuel cell to provide electrical power.
  • The integrated fuel cell combines hydrogen and oxygen to provide useful electricity + H 2 O.
  • Hydrogen is produced through a chemical reaction resulting from contact between water and a powder bag.
  • Each bag delivers 30W of power for more than one hour.

MONTREAL, Feb. 25, 2021 — Innovative silicon solutions provider HPQ Silicon Resources Inc. (“HPQ” or the “Company”) ( TSX-V: HPQ ; FWB: UGE ; Other OTC :HPQFF ), is proud to announce that it has received the TREKHY® system, a portable hydrogen-based mini-power generator, jointly developed by the French companies Apollon Solar SAS (“Apollon”) and Pragma Industries SAS (“Pragma”). While continuing to work with Apollon on the development of new generations of more efficient silicon powders for hydrogen production, HPQ signed a Memorandum of Understanding with Apollon and Pragma to study the commercial potential of the TREKHY® autonomous power generator in Canada.

The portable hydrogen-based power generator, a revolutionary product
The TREKHY® provides energy on demand. The system uses a compact fuel cell to provide electrical power. The integrated fuel cell combines hydrogen and oxygen to provide useful electricity + H 2 O. Hydrogen is produced through a chemical reaction resulting from contact between water and a powder bag. Each bag delivers 30W of power for more than one hour. ( Video of the system in operation ). In January 2021, a Japanese distributor purchased 300 TREKHY® systems to equip the survival shelters of the Japanese Civil Security.

In addition to continuing our research, development and commercialization of advanced nanoscale silicon materials, HPQ continues to look for synergistic opportunities in order to remain at the forefront of innovative processes for the storage and delivery of clean renewable energy. This new collaboration with Apollon and Pragma represents another unique opportunity to combine the expertise of HPQ in the low-cost manufacturing of silicon nanomaterials, Apollon in the manufacturing of hydrogen reactors, and Pragma in the manufacturing of fuel cells ,” said Bernard Tourillon, Chairman and CEO of HPQ Silicon Resources Inc.

Autonomous energy storage and generation capacity superior to batteries
The energy autonomy of TREKHY® depends on the number of bags used. This option significantly reduces weight and operating costs, as compared to batteries. The table below compares the weights and costs of delivered energy between:

  • Li-ion primary batteries,
  • Li-ion rechargeable batteries,
  • Zn-Air primary battery,
  • TREKHY® with 150, 300, 450, 600 powder bags.

TREKHY®, with its revolutionary fuel cell and powder technology, offers unmatched performance.

A superior clean renewable hydrogen production thanks to silicon
The current cost of manufacturing silicon nanopowders is very high and it has led Apollon and Pragma to use a less efficient, but more economical, environmentally friendly chemical powder to begin the commercialization of their system. However, the use of silicon nanopowders manufactured by HPQ’s PUREVAP TM Nano Silicon Reactor could increase the hydrogen generation potential of the system by 40%, while the use of porous silicon nanopowders could double the amount of hydrogen released by the system.

HPQ and Apollon are currently working to compare the technical and commercial potential of nanoscale and porous silicon materials to create new generations of environmentally friendly powders with better performance for hydrogen production.

HPQ’s Silicon R&D Consortium has the depth and flexibility to meet the challenges, as we strive to produce products for renewable energy storage participants and electric vehicle manufacturers, each of which is searching for cost-effective ways to increase the Silicon content of their batteries . Silicon’s potential to meet energy storage demands is undeniable, generating massive investments , and serious industry interest. We are very confident that the Silicon materials we are producing, with our expected low-cost scalable processes, will be in high demand for batteries, and by EV manufacturers and other participants in the ongoing renewable energy revolution,” added Bernard Tourillon.

Read More: https://agoracom.com/ir/HPQ-SiliconResources/forums/discussion/topics/756058-hpq-receives-its-first-mini-generator-set-based-on-clean-hydrogen-produced-by-simply-combining-water-and-a-powder-bag/messages/2305335#message

Empower Clinics $CBDT.ca $EPWCF Announces Locations of First Three Integrated Health Centres in Ontario. Each Location Anticipated to Generate Approximately $3,000,000 In Revenue. Further Locations to Be Announced $WELL.ca $DOC.ca $DOCRF $VMD.ca

Posted by AGORACOM-JC at 8:01 AM on Thursday, February 25th, 2021

Launch Confirms Empower Stated Strategy To Execute National Clinic Expansion Following Canadian Clinics Acquisition And Partnership Announcements in 2021

  • Announce the launch of its first three integrated health centres in Ontario, Canada with each location expected to generate $2,560,000 – $3,600,000 in annual revenue.
  • Advanced discussions are currently underway on multiple additional locations as the Company begins the rollout of its national clinic expansion strategy.

VANCOUVER, BC / February 25, 2021 / EMPOWER CLINICS INC. (CBDT:CSE) (8EC:Frankfurt) (EPWCF:OTCQB) (“Empower” or the “Company“) an integrated healthcare company serving patients through medical centres, telemedicine platforms, operating a high complexity medical diagnostics laboratory processing thousands of COVID-19 specimens, is pleased to announce the launch of its first three integrated health centres in Ontario, Canada with each location expected to generate $2,560,000 – $3,600,000 in annual revenue. Advanced discussions are currently underway on multiple additional locations as the Company begins the rollout of its national clinic expansion strategy.

THREE ONTARIO LOCATIONS AND TWELVE PHYSICIANS COMMITTED TO OPEN

The locations and approximate sizes of the integrated health centres are as follows:

1) Etobicoke, Ontario Approximately 2,700 sq ft.

2) London, Ontario Approximately 3,100 sq ft.

3) Etobicoke, ON (site two) Approximately 2,900 sq ft.

“Dr. Aviv Tsimmerman and Dr. Jordan Rabinowitz are executing on our growth initiatives, they are achieving milestones, they are opening our healthcare centers.” said Steven McAuley, Chairman & CEO. “Our approach is based on patients and their needs, the delivery of care, an improved healthcare model, that provides advanced technology and access for an improved healthcare outcome.”

Each location is expected to host 4-6 physicians. Empower has already secured commitments from twelve (12) physicians to date, with numerous additional medical doctors and para-medical practitioners expressing interest to join the team.

“Having a strategic blend of health professionals allows us to provide an unparalleled integrative healthcare experience.” stated Dr. Jordan Rabinowitz, Chief Operating Officer. He further states, “This defines our path to assist millions of Canadians nationwide.”

HEALTH CARE SERVICES TO BE DELIVERED AND ANTICIPATED REVENUE MODEL

Empower will be opening primary care, plus para-medical healthcare services, with a target of four (4) to six (6) medical doctors and four (4) to six (6) paramedical practitioners per location.

Primary care services include:

  • Family physicians
  • Walk-in physicians
  • Tele-medicine and virtual care

Empower expects to generate $400,000 – $600,000 in annual revenue per MD, per location, which equates to a revenue range between $1,600,000 – $2,400,000 annually per location.

Paramedical services include:

  • Chiropractic
  • Physiotherapy
  • Registered Massage Therapy
  • Chiropody
  • Acupuncturists
  • Osteopaths
  • Nutritionists

Empower expects to generate $960,000 – $1,200,000 in annual revenue per location.

Together, when each location is fully operational, Empower expects to generate $2,560,000 – $3,600,000 in annual revenue per location.

ADDITIONAL HEALTH CARE SERVICES EXPECTED TO BE ADDED

Given the anticipated expansion and penetration of Empower Clinics into the Canadian market, the Company intends to continue adding valuable specialized medical services to strengthen the quality of healthcare at each location that can include:

  • Dermatology
  • Cardiology

Empower is currently in advanced discussions with potential partners in each of these specialty areas and believes they hold the potential to add significant value to the operations of each healthcare centre.

This press release is available on the Empower Clinics Verified Forum on AGORACOM for shareholder discussion, questions and engagement with management https://agoracom.com/ir/EmpowerClinics

ABOUT EMPOWER:

Empower is an integrated healthcare company that provides body and mind wellness for patients through its clinics, with digital and telemedicine care, and world-class medical diagnostics laboratories. Supported by an experienced leadership team, Empower is aggressively growing its clinical and digital presence across North America. Our Health & Wellness and Diagnostics & Technology business units are positioned to positively impact the integrated health of our patients, while simultaneously providing long term value for our shareholders.

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

CONTACTS:

Investors:
Steven McAuley
CEO
[email protected]
604-789-2146

Investors:
Tamara Mason
Business Development & Communications
[email protected]
416-671-5617

Read more: https://agoracom.com/ir/EmpowerClinics/forums/discussion/topics/756054-empower-clinics-announces-locations-of-first-three-integrated-health-centres-in-ontario-each-location-anticipated-to-generate-approximately-3m/messages/2305329#message

Chilean Metals $CMX.ca Closes NISK Acquisition Providing the Company a High-Grade Historical Nickel Copper Cobalt PGE Resource $FCC.ca $CCW.ca $FPX.ca

Posted by AGORACOM at 7:42 AM on Thursday, February 25th, 2021

Chilean Metals Inc. (“Chilean Metals,” “CMX” or the “Company”) (TSXV:CMX)(SSE:CMX)(MILA:CMX) s pleased to announce it has received TSXV conditional approval on its announced agreement to acquire 80% of the NISK property via a series of option payments and work commitments as further detailed below.

Option Terms:

Grant of first option

Critical Elements Lithium Corp. (“Critical Elements”) (CRE)(CRECF)(F12) has granted to Chilean Metals, as the “Optionee”, the exclusive right and option to acquire, on or before the date that is three (3) years from the TSX.V approval (the “Effective Date”) (the “First Option Period“), an initial 50% Earned Interest in the Property (the “First Option“), free and clear of all Encumbrances other than the Permitted Encumbrances and the Royalty, subject to the terms and conditions in this Agreement.

Requirements to Exercise the First Option

In order to acquire the 50% Earned Interest under the First Option, the Optionee must:

a. make cash payments totaling $500,000 to Critical Elements (the “Cash Payments“) on or before the dates set out below:
i. a non-refundable amount of $25,000 on the date of execution of the agreement; (COMPLETED)
ii. an amount of $225,000 within a delay of five (5) Business Days following the Effective Date; and (COMPLETED)
iii. an amount $250,000 within a delay of six (6) months from the Effective Date;
b. issue to Critical Elements within five (5) Business Days following the Effective Date, 12,051,770 Shares (the “Share Payment“) of the Optionee. The Shares issued will be issued as fully paid and non-assessable free and clear of all liens, charges, and Encumbrances, and subject only to a four-month and one-day resale restriction under applicable Securities Laws and the policies of the TSXV;
c. incur an aggregate of $2,800,000 of Work Expenditures on the Property on or before the dates set out below:
i. $500,000 in Work Expenditures on or before the date that is one (1) year from Effective Date;
ii. $800,000 in Work Expenditures on or before the date that is two (2) years from Effective Date; and
iii. $1,500,000 in Work Expenditures on or before the date that is three (3) years from Effective Date; and

Upon the Optionee having completed the Cash Payments, the Share Payment and incurred or funded the Work Expenditures on or before the expiry of the First Option Period, the Optionee may exercise the First Option by delivering notice to Critical Elements to that effect and confirming exercise of the First Option (the “First Option Exercise Notice“). Upon delivery of the First Option Exercise Notice, the Optionee shall have earned a 50% Earned Interest in the Property.

Grant of second option

Subject to the Optionee having exercised the First Option, Critical Elements also grants to the Optionee the exclusive right and option (the “Second Option”) to increase its Earned Interest in and to the Property from 50% to 80% by incurring or funding additional Work Expenditures for an amount of $2,200,000, including the delivery of a Resource Estimate, for a period commencing on the delivery of the First Option Exercise Notice and ending on the date that is four (4) years from Effective Date (the “Second Option Period”).

Following the exercise of the Second Option, until such time as a definitive Feasibility Study (the “Definitive Feasibility Study“) regarding extraction and production activities on the Property is delivered to the Joint Venture, Critical Elements shall maintain a 20% non-dilutive interest in the Joint Venture and shall not contribute to any Joint Venture costs.

Operatorship

During the currency of the Agreement, except as otherwise contemplated under the Agreement, Chilean Metals shall act as the operator (the “Operator“), and as such, shall be responsible for carrying out and administering the Work Expenditures on the Property, in accordance with work programs (the “Programs“) approved by the Technical Committee. The Operator shall be entitled to receive a management fee equal to 10% of the amount of Work Expenditures incurred on internal work and equal to 5% of the amount of Work Expenditures incurred on contract work carried by third-party contractors or consultants.

In the event, Chilean Metals exercises the First Option and subsequently elects not to exercise the Second Option, or in the event, the Second Option is terminated, whichever the case, Chilean Metal’s right to act as Operator shall immediately terminate and Critical Elements shall become the Operator for the future conduct of Work Expenditures and Programs on the Property.

Royalty

Following the exercise of the First Option by Chilean, and in addition to the obligations of Chilean under the First and Second Option, if applicable, Critical Elements shall receive, in the event of a Lithium discovery, a royalty equal to 2% net smelter returns (the “Royalty“) resulting from the extraction and production of Lithium products, including Lithium ore, concentrate and chemical, resulting from the extraction and production activities on the Property, including transformation into chemical products. Chilean shall have the right at any time to purchase 50% of the Royalty and thereby reduce the Royalty to 1% by paying to Critical Elements a total cash amount of $2,000,000.

Read More: https://agoracom.com/ir/ChileanMetals/forums/discussion/topics/756056-chilean-metals-closes-nisk-acquisition-providing-the-company-a-high-grade-historical-nickel-copper-cobalt-pge-resource/messages/2305331#message

Valeo Pharma $VPH $VPHIF Reports its 2020 Fourth Quarter and Year-End Results and Highlights $HLS.ca $MDP.ca $GUD.ca $RX.ca

Posted by AGORACOM-JC at 5:52 PM on Wednesday, February 24th, 2021
Valeo Pharma (@valeo_pharma) | Twitter
  • Q4-20 net revenues of $2.2 million , up 76 % vs Q4-19, 2020 net revenues of $7.5 million up 14% vs 2019
  • Hiring of Frederic Fasano as new President and COO
  • Successfully launched 4 new products during FY-20
  • Redesca ® , Redesca HP ® and Amikacin approved by Health Canada subsequent to year-end
  • $10.8 million raised in 2020 from bought deal offering and over-subscribed private placements
  • Valeo’s shares now trading on the US-OTCQB exchange under “VPHIF”

MONTREAL , Feb. 24, 2021 – Valeo Pharma Inc . (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) (” Valeo ” or the ” Company “), a Canadian specialty pharmaceutical company, today reported its financial results for the fourth quarter and year-ended October 31, 2020 .

“Valeo accomplished key objectives in 2020 which sets the stage for strong growth in 2021. In addition to Hesperco TM , we launched three strategic products and secured regulatory approvals for Redesca ® ,Redesca HP ® and Amikacin, all of which will be launched in the first half of 2021. We expect that these products will contribute significant revenues and margins in 2021”, said Steve Saviuk , Valeo’s CEO. “Our vision of building an anchor Canadian pharmaceutical company through therapeutic innovation is solidifying as we continue to build our commercial portfolio in therapeutic areas of focus.”

Commenting on the fourth quarter and 2020 results, Luc Mainville , Senior Vice-President and Chief Financial Officer said, “As evidenced by our revenues increase and net loss decrease of the fourth quarter, our efforts towards becoming a profitable EBITDA company are starting to bear fruit. During the last portion of 2020, the launch of new products such as Ametop ® and Yondelis® in Canada and Sodium Ethacrynate in the U.S., has contributed new revenues and margins with nominal increase to our operating expenses. The execution of our growth strategy is positioning the Company for a very successful year in 2021”.

Read More: https://agoracom.com/ir/ValeoPharma/forums/discussion/topics/756027-valeo-pharma-reports-its-2020-fourth-quarter-and-year-end-results-and-highlights/messages/2305248#message

Arctic Star $ADD.ca Further Increases Financing to $1.3M $RIO $DIAM.ca $NAR.ca $MPVD.ca

Posted by AGORACOM at 2:10 PM on Wednesday, February 24th, 2021
Arctic star logo
  • Arctic Star Announces Further Increase To Non-Brokered Private Placement
  • Amended the terms of its previously announced financing described in its press releases of Feb. 2, 2021, Feb. 4, 2021, and Feb. 19, 2021
  • Issue up to 26 million units for gross proceeds of up to $1.3-million.

Arctic Star Exploration Corp. has amended the terms of its previously announced financing described in its press releases of Feb. 2, 2021, Feb. 4, 2021, and Feb. 19, 2021. The company previously disclosed that it would issue up to 17 million units at a price of five cents per unit for gross proceeds of $850,000. Due to further increased demand, the company has increased the number of units to be issued, such that it will issue up to 26 million units for gross proceeds of up to $1.3-million.

Each unit will comprise one common share in the capital of the company and one non-transferable share purchase warrant. Each warrant will entitle the holder to purchase one additional share in the capital of the company for a period of 24 months from the closing date at an exercise price of 10 cents.

All securities will be subject to a four-month hold period from the closing date. The private placement is subject to TSX Venture Exchange approval.

The company intends to use the proceeds from the private placement for exploration on the Diagras diamond project and for general working capital.

Else Nutrition $BABY.ca $BABYF Named a Top TSX Venture Company for 2021 $VERY.ca $MEAT.ca $EATS.ca $VEGN.ca

Posted by AGORACOM-JC at 10:45 AM on Wednesday, February 24th, 2021
http://blog.agoracom.com/wp-content/uploads/2020/03/else-square-150x150.png
  • Named to the 2021 TSX Venture 50®, a list of the top 50 companies listed on the TSX Venture Exchange.
  • TSX Venture 50® is made-up of the top 10 companies listed on the TSX Venture Exchange, in each of five major industry sectors – Clean Technology and Life Sciences, Diversified Industries, Energy, Mining, and Technology.

VANCOUVER, BC , Feb. 24, 2021 – ELSE NUTRITION HOLDINGS INC. (TSXV: BABY ) (OTCQX: BABYF ) (FSE: 0YL ) (“Else” or the “Company”) the plant-based baby, toddler and children nutrition company ,  announces it has been named to the 2021 TSX Venture 50®, a list of the top 50 companies listed on the TSX Venture Exchange.

The TSX Venture 50® is made-up of the top 10 companies listed on the TSX Venture Exchange, in each of five major industry sectors – Clean Technology and Life Sciences, Diversified Industries, Energy, Mining, and Technology.

Else Nutrition was named as the top company within the diversified industries category. Each of the companies chosen for the 2020 TSX Venture 50® had seen “impressive growth over the past year, offered strong return to their shareholders and are actively traded in the market.”

“We’re thrilled for this recognition in the 2021 TSX Venture50® for the value we’ve been able to provide our shareholders,” said Hamutal Yitzhak , CEO and Co-Founder of Else Nutrition. “We’re very excited to continue to execute on our growth plan throughout the rest of 2021, with growth engines spanning distribution, product portfolio, and geographies,” she added.

The 2021 Venture 50 winners were selected based on year-over-year performance across three equally-weighted criteria: market capitalization growth, share price appreciation and trading volume for the year ended December 31, 2020 .

Read more: https://agoracom.com/ir/ElseNutritionHoldings/forums/discussion/topics/755972-else-nutrition-named-a-top-tsx-venture-company-for-2021/messages/2305122#message